131 related articles for article (PubMed ID: 29735783)
1. Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines.
Uribe D; Cardona A; Esposti DD; Cros MP; Cuenin C; Herceg Z; Camargo M; Cortés-Mancera FM
Ann Hepatol; 2018; 17(3):444-460. PubMed ID: 29735783
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Chan DW; Lee JM; Chan PC; Ng IO
Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
4. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
5. Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia.
Moskalev EA; Luckert K; Vorobjev IA; Mastitsky SE; Gladkikh AA; Stephan A; Schrenk M; Kaplanov KD; Kalashnikova OB; Pötz O; Joos TO; Hoheisel JD
BMC Cancer; 2012 Jun; 12():213. PubMed ID: 22672427
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
7. Effect of trichostatin A on anti HepG2 liver carcinoma cells: inhibition of HDAC activity and activation of Wnt/β-Catenin signaling.
Shi QQ; Zuo GW; Feng ZQ; Zhao LC; Luo L; You ZM; Li DY; Xia J; Li J; Chen DL
Asian Pac J Cancer Prev; 2014; 15(18):7849-55. PubMed ID: 25292076
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
10. The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.
Mostovich LA; Prudnikova TY; Kondratov AG; Gubanova NV; Kharchenko OA; Kutsenko OS; Vavilov PV; Haraldson K; Kashuba VI; Ernberg I; Zabarovsky ER; Grigorieva EV
Epigenetics; 2012 Aug; 7(8):930-9. PubMed ID: 22805760
[TBL] [Abstract][Full Text] [Related]
11. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
14. The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24).
Varol N; Konac E; Onen IH; Gurocak S; Alp E; Yilmaz A; Menevse S; Sozen S
DNA Cell Biol; 2014 Jul; 33(7):408-17. PubMed ID: 24665856
[TBL] [Abstract][Full Text] [Related]
15. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
[TBL] [Abstract][Full Text] [Related]
16. Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus.
Rogacki K; Kasprzak A; Stępiński A
Pol J Pathol; 2015 Mar; 66(1):9-21. PubMed ID: 26017875
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.
Zhang Y; Feng J; Mi Y; Fan W; Qin R; Mei Y; Jin G; Mao J; Zhang H
Drug Metab Dispos; 2024 May; 52(6):555-564. PubMed ID: 38565301
[TBL] [Abstract][Full Text] [Related]
18. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.
Jiang X; Tan J; Li J; Kivimäe S; Yang X; Zhuang L; Lee PL; Chan MT; Stanton LW; Liu ET; Cheyette BN; Yu Q
Cancer Cell; 2008 Jun; 13(6):529-41. PubMed ID: 18538736
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
Quan H; Zhou F; Nie D; Chen Q; Cai X; Shan X; Zhou Z; Chen K; Huang A; Li S; Tang N
Oncogene; 2014 May; 33(22):2826-35. PubMed ID: 23770846
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
